Apex Medical Corp. (4106.TW)
TWD 21.55
(2.62%)
TWD 21.55
(2.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 152.17 Million TWD | -5.72% |
| 2022 | 161.4 Million TWD | 57.86% |
| 2021 | 102.24 Million TWD | -2.24% |
| 2020 | 104.58 Million TWD | 18.96% |
| 2019 | 87.92 Million TWD | -18.9% |
| 2018 | 108.41 Million TWD | -8.33% |
| 2017 | 118.26 Million TWD | -3.46% |
| 2016 | 122.5 Million TWD | -27.4% |
| 2015 | 168.74 Million TWD | -5.42% |
| 2014 | 178.41 Million TWD | 33.68% |
| 2013 | 133.46 Million TWD | -31.98% |
| 2012 | 196.22 Million TWD | -15.63% |
| 2011 | 232.56 Million TWD | 28.71% |
| 2010 | 180.68 Million TWD | -14.85% |
| 2009 | 212.18 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 40.01 Million TWD | 50.29% |
| 2024 Q2 | 21.24 Million TWD | -46.91% |
| 2023 Q3 | 23.95 Million TWD | -52.89% |
| 2023 Q4 | 26.62 Million TWD | 11.12% |
| 2023 FY | 152.17 Million TWD | -5.72% |
| 2023 Q1 | 50.73 Million TWD | 162.09% |
| 2023 Q2 | 50.85 Million TWD | 0.25% |
| 2022 Q2 | 51.68 Million TWD | 68.44% |
| 2022 Q4 | 19.35 Million TWD | -67.57% |
| 2022 FY | 161.4 Million TWD | 57.86% |
| 2022 Q3 | 59.69 Million TWD | 15.5% |
| 2022 Q1 | 30.68 Million TWD | 303.64% |
| 2021 Q3 | 30.95 Million TWD | -10.75% |
| 2021 Q4 | 7.6 Million TWD | -75.44% |
| 2021 Q1 | 29.01 Million TWD | 108.28% |
| 2021 Q2 | 34.67 Million TWD | 19.5% |
| 2021 FY | 102.24 Million TWD | -2.24% |
| 2020 Q2 | 55.27 Million TWD | 643.88% |
| 2020 Q1 | 7.43 Million TWD | -61.53% |
| 2020 FY | 104.58 Million TWD | 18.96% |
| 2020 Q4 | 13.93 Million TWD | -50.16% |
| 2020 Q3 | 27.95 Million TWD | -49.42% |
| 2019 Q3 | 12.55 Million TWD | -33.41% |
| 2019 FY | 87.92 Million TWD | -18.9% |
| 2019 Q1 | 37.19 Million TWD | 5.36% |
| 2019 Q2 | 18.85 Million TWD | -49.31% |
| 2019 Q4 | 19.31 Million TWD | 53.83% |
| 2018 Q1 | 23.09 Million TWD | 15.78% |
| 2018 FY | 108.41 Million TWD | -8.33% |
| 2018 Q4 | 35.3 Million TWD | 35.03% |
| 2018 Q3 | 26.14 Million TWD | 9.55% |
| 2018 Q2 | 23.86 Million TWD | 3.36% |
| 2017 Q4 | 19.94 Million TWD | -13.85% |
| 2017 Q1 | 26.39 Million TWD | 66.74% |
| 2017 Q3 | 23.15 Million TWD | -52.53% |
| 2017 Q2 | 48.77 Million TWD | 84.81% |
| 2017 FY | 118.26 Million TWD | -3.46% |
| 2016 FY | 122.5 Million TWD | -27.4% |
| 2016 Q1 | 47.09 Million TWD | 2.09% |
| 2016 Q2 | 33.22 Million TWD | -29.46% |
| 2016 Q3 | 26.35 Million TWD | -20.67% |
| 2016 Q4 | 15.82 Million TWD | -39.94% |
| 2015 Q4 | 46.13 Million TWD | 181.66% |
| 2015 Q3 | 16.37 Million TWD | -66.41% |
| 2015 Q2 | 48.76 Million TWD | -15.15% |
| 2015 Q1 | 57.47 Million TWD | 167.39% |
| 2015 FY | 168.74 Million TWD | -5.42% |
| 2014 Q4 | 21.49 Million TWD | -54.89% |
| 2014 Q3 | 47.64 Million TWD | -9.33% |
| 2014 Q1 | 56.73 Million TWD | 34.41% |
| 2014 FY | 178.41 Million TWD | 33.68% |
| 2014 Q2 | 52.54 Million TWD | -7.38% |
| 2013 Q4 | 42.21 Million TWD | 231.45% |
| 2013 FY | 133.46 Million TWD | -31.98% |
| 2013 Q3 | 12.73 Million TWD | -65.68% |
| 2013 Q2 | 37.1 Million TWD | -10.4% |
| 2013 Q1 | 41.41 Million TWD | 43.48% |
| 2012 Q1 | 55.86 Million TWD | 0.24% |
| 2012 FY | 196.22 Million TWD | -15.63% |
| 2012 Q3 | 40.15 Million TWD | -35.64% |
| 2012 Q2 | 62.39 Million TWD | 11.69% |
| 2012 Q4 | 28.86 Million TWD | -28.12% |
| 2011 Q1 | 75.65 Million TWD | 285.81% |
| 2011 FY | 232.56 Million TWD | 28.71% |
| 2011 Q2 | 46.7 Million TWD | -38.26% |
| 2011 Q3 | 54.47 Million TWD | 16.63% |
| 2011 Q4 | 55.73 Million TWD | 2.32% |
| 2010 Q3 | 46.02 Million TWD | -29.05% |
| 2010 FY | 180.68 Million TWD | -14.85% |
| 2010 Q4 | 19.6 Million TWD | -57.39% |
| 2010 Q1 | 50.17 Million TWD | 0.0% |
| 2010 Q2 | 64.86 Million TWD | 29.28% |
| 2009 FY | 212.18 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 746.6 Million TWD | 79.618% |
| OK Biotech Co., Ltd. | 2.94 Million TWD | -5061.872% |
| Applied BioCode Corporation | -164.19 Million TWD | 192.675% |